LENSAR (NASDAQ:LNSR) Director Sells $54,476.17 in Stock

LENSAR logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • LENSAR director Elizabeth O’Farrell sold 10,961 shares for $54,476 at an average price of $4.97, reducing her holdings by 13.99% to 67,368 shares.
  • The stock fell to $4.64, near its 12-month low of $4.30. In its latest quarter, LENSAR reported an adjusted loss of $0.38 per share, missing estimates, and revenue of $14.13 million, slightly below consensus.
  • Analysts’ consensus rating is Hold, with an average price target of $11.00; recent ratings include two Buys and one Sell.
  • Five stocks to consider instead of LENSAR.

LENSAR, Inc. (NASDAQ:LNSR - Get Free Report) Director Elizabeth O'farrell sold 10,961 shares of the stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $4.97, for a total transaction of $54,476.17. Following the completion of the transaction, the director owned 67,368 shares of the company's stock, valued at $334,818.96. This represents a 13.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

LENSAR Stock Performance

Shares of LNSR stock traded down $0.21 during midday trading on Thursday, reaching $4.64. 35,909 shares of the company were exchanged, compared to its average volume of 90,536. LENSAR, Inc. has a 12 month low of $4.30 and a 12 month high of $12.94. The company has a market cap of $57.04 million, a P/E ratio of -11.60 and a beta of 1.03. The company's 50 day moving average price is $6.22 and its two-hundred day moving average price is $7.06.

LENSAR (NASDAQ:LNSR - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.28). LENSAR had a net margin of 56.07% and a return on equity of 1,254.25%. The company had revenue of $14.13 million during the quarter, compared to the consensus estimate of $14.30 million.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LNSR shares. Loop Capital set a $11.00 price objective on LENSAR in a research note on Monday, September 28th. Lake Street Capital reaffirmed a "buy" rating and set a $13.00 target price on shares of LENSAR in a report on Thursday, August 13th. Weiss Ratings lowered LENSAR from a "sell (d+)" rating to a "sell (d)" rating in a report on Tuesday. BTIG Research dropped their price target on shares of LENSAR from $10.00 to $9.00 and set a "buy" rating on the stock in a research report on Tuesday, November 10th. Finally, Wall Street Zen downgraded shares of LENSAR from a "hold" rating to a "sell" rating in a report on Saturday, November 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $11.00.

View Our Latest Report on LNSR

Institutional Investors Weigh In On LENSAR

A number of institutional investors and hedge funds have recently modified their holdings of LNSR. Bank of New York Mellon Corp acquired a new position in shares of LENSAR in the 2nd quarter worth $58,000. Engineers Gate Manager LP purchased a new stake in shares of LENSAR during the second quarter valued at $63,000. Sanctuary Advisors LLC acquired a new position in shares of LENSAR in the 2nd quarter valued at $96,000. State of Wyoming acquired a new position in shares of LENSAR in the 3rd quarter valued at $110,000. Finally, Royal Bank of Canada increased its stake in LENSAR by 78.2% in the 1st quarter. Royal Bank of Canada now owns 20,095 shares of the company's stock worth $120,000 after purchasing an additional 8,818 shares in the last quarter. Institutional investors and hedge funds own 40.15% of the company's stock.

LENSAR Company Profile

(Get Free Report)

LENSAR, Inc. develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye's natural lens. The company's products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LENSAR Right Now?

Before you consider LENSAR, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list.

While LENSAR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines